F.X. Vollenweider

873 total citations
23 papers, 597 citations indexed

About

F.X. Vollenweider is a scholar working on Clinical Psychology, Cellular and Molecular Neuroscience and Toxicology. According to data from OpenAlex, F.X. Vollenweider has authored 23 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Clinical Psychology, 12 papers in Cellular and Molecular Neuroscience and 4 papers in Toxicology. Recurrent topics in F.X. Vollenweider's work include Psychedelics and Drug Studies (13 papers), Neurotransmitter Receptor Influence on Behavior (12 papers) and Forensic Toxicology and Drug Analysis (4 papers). F.X. Vollenweider is often cited by papers focused on Psychedelics and Drug Studies (13 papers), Neurotransmitter Receptor Influence on Behavior (12 papers) and Forensic Toxicology and Drug Analysis (4 papers). F.X. Vollenweider collaborates with scholars based in Switzerland, Germany and Slovenia. F.X. Vollenweider's co-authors include Felix Hasler, Daniel Bourquin, Rudolf Brenneisen, T. Bär, Karl‐Johan Lindner, S. Ludewig, Erich Studerus, Daniel Hell, Matthias E. Liechti and Alex Gamma and has published in prestigious journals such as Biological Psychiatry, Neuropsychopharmacology and Schizophrenia Research.

In The Last Decade

F.X. Vollenweider

22 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F.X. Vollenweider Switzerland 9 443 353 198 104 82 23 597
Andreas Bäbler Switzerland 3 631 1.4× 512 1.5× 303 1.5× 59 0.6× 83 1.0× 3 802
Filip Tylš Czechia 12 403 0.9× 399 1.1× 214 1.1× 87 0.8× 110 1.3× 27 742
Joseph P. Barsuglia United States 14 424 1.0× 205 0.6× 215 1.1× 43 0.4× 73 0.9× 18 570
Dominique Holstein Switzerland 5 514 1.2× 281 0.8× 310 1.6× 29 0.3× 84 1.0× 5 637
Robin von Rotz Switzerland 10 282 0.6× 184 0.5× 204 1.0× 65 0.6× 63 0.8× 17 427
Collin Reiff United States 8 499 1.1× 195 0.6× 240 1.2× 40 0.4× 60 0.7× 11 653
Nadia R. P. W. Hutten Netherlands 14 695 1.6× 424 1.2× 385 1.9× 119 1.1× 55 0.7× 25 868
B. Thelen Germany 7 219 0.5× 219 0.6× 75 0.4× 44 0.4× 77 0.9× 8 362
Lysia Demetriou United Kingdom 13 627 1.4× 438 1.2× 368 1.9× 29 0.3× 148 1.8× 20 961
Peter H. Addy United States 8 257 0.6× 221 0.6× 90 0.5× 160 1.5× 40 0.5× 10 506

Countries citing papers authored by F.X. Vollenweider

Since Specialization
Citations

This map shows the geographic impact of F.X. Vollenweider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F.X. Vollenweider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F.X. Vollenweider more than expected).

Fields of papers citing papers by F.X. Vollenweider

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F.X. Vollenweider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F.X. Vollenweider. The network helps show where F.X. Vollenweider may publish in the future.

Co-authorship network of co-authors of F.X. Vollenweider

This figure shows the co-authorship network connecting the top 25 collaborators of F.X. Vollenweider. A scholar is included among the top collaborators of F.X. Vollenweider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F.X. Vollenweider. F.X. Vollenweider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Preller, Katrin H., Marcus Herdener, Thomas Pokorny, et al.. (2016). The role of the serotonin 2A receptor in the fabric and modulation of personal meaning in lysergic acid diethylamide (LSD)-induced states. European Neuropsychopharmacology. 26. S299–S300. 3 indexed citations
2.
Grimm, O., et al.. (2016). Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination task. European Neuropsychopharmacology. 26. S218–S218. 1 indexed citations
3.
Preller, Katrin H., et al.. (2015). The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making. European Psychiatry. 30. 22–22. 16 indexed citations
4.
Kraehenmann, Rainer, Katrin H. Preller, Erich Seifritz, & F.X. Vollenweider. (2014). P.1.g.005 Serotonergic modulation of emotion processing by the mixed 5-HT1A/2A receptor agonist psilocybin reduces amygdala activation to negative stimuli – a pharmacological fMRI study. European Neuropsychopharmacology. 24. S204–S205. 1 indexed citations
5.
Hasler, Felix, Olga Kuznetsova, Р. Н. Красикова, et al.. (2008). GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Applied Radiation and Isotopes. 67(4). 598–601. 8 indexed citations
6.
Hasler, Felix, Erich Studerus, Karl‐Johan Lindner, S. Ludewig, & F.X. Vollenweider. (2008). Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology. 23(8). 923–935. 43 indexed citations
7.
8.
Vollenweider, F.X., et al.. (2003). P.2.107 Brain activation patterns during prepulse inhibition (PPI) in first episode schizophrenia and health controls using H2 15O-PET. European Neuropsychopharmacology. 13. S327–S327. 1 indexed citations
9.
Umbricht, Daniel, et al.. (2000). 177. NMDA and 5-HT2A receptor dysfunction in working memory deficits in schizophrenia. Biological Psychiatry. 47(8). S53–S53. 2 indexed citations
10.
Vollenweider, F.X., et al.. (2000). 423. 5-HT2 receptor activation: a common denominator of the NMDA antagonist and 5-HT2A agonist models of psychosis?. Biological Psychiatry. 47(8). S129–S130. 1 indexed citations
11.
Vollenweider, F.X., Daniel Umbricht, M.A. Geyer, & Daniel Hell. (2000). Effects of NMDA-antagonists and 5-HT2A-agonists on prepulse inhibition in human volunteers. Schizophrenia Research. 41(1). 147–147. 6 indexed citations
12.
Umbricht, Daniel, et al.. (2000). How specific are deficits in generation of mismatch negativity to schizophrenia?. Schizophrenia Research. 41(1). 31–32. 2 indexed citations
13.
Umbricht, Daniel, et al.. (2000). Investigations into the neurobiology of information processing deficits in schizophrenia. Schizophrenia Research. 41(1). 290–291. 1 indexed citations
14.
Vollenweider, F.X.. (1999). 5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride. Neuropsychopharmacology. 20(5). 424–433. 217 indexed citations
15.
Zessin, J., Simon M. Ametamey, J. Steinbach, et al.. (1999). Efficient synthesis of enantiomerically pure thioester precursors of [11C]McN-5652 from racemic McN-5652. Journal of Labelled Compounds and Radiopharmaceuticals. 42(13). 1301–1312. 12 indexed citations
16.
17.
Liechti, Matthias E., Ch. Baumann, Daniel Hell, & F.X. Vollenweider. (1999). Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. European Neuropsychopharmacology. 9. 341–342. 8 indexed citations
18.
Vollenweider, F.X.. (1998). Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research. Pharmacopsychiatry. 31(S 2). 92–103. 62 indexed citations
19.
Ametamey, Simon M., F.X. Vollenweider, J. T. Patt, et al.. (1998). 11C-radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formation. Journal of Labelled Compounds and Radiopharmaceuticals. 41(7). 585–594. 11 indexed citations
20.
Hasler, Felix, Daniel Bourquin, Rudolf Brenneisen, T. Bär, & F.X. Vollenweider. (1997). Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae. 72(3). 175–184. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andreas Bäbler Breakdown of academic impact, for papers by Filip Tylš Breakdown of academic impact, for papers by Joseph P. Barsuglia Breakdown of academic impact, for papers by Dominique Holstein Breakdown of academic impact, for papers by Robin von Rotz Breakdown of academic impact, for papers by Collin Reiff Breakdown of academic impact, for papers by Nadia R. P. W. Hutten Breakdown of academic impact, for papers by B. Thelen Breakdown of academic impact, for papers by Lysia Demetriou Breakdown of academic impact, for papers by Peter H. Addy
Rankless by CCL
2026